FDA approves Zydus Cadila’s generic Diamox
Zydus Cadila has received the Food and Drug Administration’s clearance for its generic Diamox (acetazolamide for injection). The generic of Teva’s branded drug was approved in a strength of 500 mg per single-dose vial.
Acetazolamide is a carbonic anhydrase inhibitor, effective in the control of fluid secretion in some types of glaucoma, treatment of certain convulsive disorders, including epilepsy, and promotion of diuresis in such instances of abnormal fluid retention as cardiac edema.
The product will be manufactured at the group’s formulations manufacturing facility at Moraiya, Ahmedabad.
No comments found